Fig. 1.

Longitudinal analysis of ALT and HCV-RNA during therapy. Changes (%) in plasma ALT (a) and change in HCV-RNA values (b) from baseline during the duration of the study. On the y-axis are the % change in ALT (U/l) and the ΔHCV-RNA (log₁₀ IU/ml) depicted. On the x-axis the weeks of the study are shown. Patients treated with the caspase-inhibitor GS-9450 are represented by the solid black lines and black dots and those receiving placebo are represented by the black dotted lines and open squares